Optimal scheduling of cancer surgery and adjuvant therapy

癌症手术和辅助治疗的最佳安排

• 批准号: nhmrc : 1099546
• 负责人: A/Pr Michele Teng
• 金额: $ 45.74万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/optimal-scheduling-cancer-adjuvant-therapy/662459
• 关键词: Optimal; scheduling; cancer; surgery; adjuvant

Cancer surgery is the most effective single modality for curing patients. Unfortunately, 50% of patients will relapse after surgery due to metastases and require further therapy. Immunotherapies such as Ipilimumab/Nivolumab have been revolutionary in causing long term tumour regression and potential cures in advanced cancers. We have preliminary data showing immunotherapies given before surgery is more effective in preventing metastases and we aim to understand the reason for its effectiveness.

癌症手术是治愈患者最有效的单一方式。不幸的是，50%的患者术后会因转移而复发，需要进一步治疗。伊匹单抗/纳武单抗等免疫疗法在导致肿瘤长期消退和晚期癌症的潜在治愈方面具有革命性意义。我们的初步数据显示，手术前给予免疫疗法在预防转移方面更有效，我们的目标是了解其有效性的原因。